Increased follistatin levels after oral contraceptive treatment in obese and non-obese women with polycystic ovary syndrome

Mei Jou Chen, Wei Shiung Yang, Hsin Fu Chen, Jahn Jahn Kuo, Hong Nerng Ho, Yu Shih Yang, Shee Uan Chen

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: Follistatin levels have recently been considered as a marker for inflammation. Our objective was to evaluate the level of circulating follistatin and high-sensitivity C-reactive protein (hsCRP) in women with polycystic ovary syndrome (PCOS) after oral contraceptive (OC) treatment. Methods: A total of 56 Taiwanese women with PCOS were enrolled in this prospective observational study in which they were treated for 3 months with OCs (ethinyl estradiol-cyproterone acetate). Blood samples were taken at baseline after treatment during the withdrawal bleed. Body mass index (BMI), lipid profiles, plasma follistatin, hsCRP, fasting glucose, insulin for the homeostasis model assessment of insulin resistance (HOMA-IR) and hormone profiles were measured and analyzed. Results: Total testosterone, free androgen index (FAI), dehydroepiandrosterone sulfate (DHEAS), follicle-stimulating hormone (FSH), luteinizing hormone (LH) and estradiol levels were significantly lower, but total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides, circulating follistatin and hsCRP were significantly higher than baseline in women with PCOS after treatment with OCs. An elevation of fasting insulin, HOMA-IR and hsCRP after OC treatment was more evident in non-obese than obese women, whereas the elevation of follistatin was significant in both obese and non-obese women. Follistatin and hsCRP levels all showed significant correlations with each other at baseline and after treatment. The differences in follistatin and hsCRP levels from baseline to after OC treatment were significantly associated with the difference in triglyceride levels. Conclusion: SBoth hsCRP and follistatin levels increase after OC treatment in women with PCOS. Follistatin seems more sensitive than hsCRP alone to represent the aggravated low-grade inflammatory status after OC treatment in obese and non-obese women with PCOS.

Original languageEnglish
Pages (from-to)779-785
Number of pages7
JournalHuman Reproduction
Volume25
Issue number3
DOIs
Publication statusPublished - Jan 1 2010
Externally publishedYes

Fingerprint

Follistatin
Polycystic Ovary Syndrome
Oral Contraceptives
C-Reactive Protein
Therapeutics
Insulin Resistance
Fasting
Triglycerides
Homeostasis
Insulin
Dehydroepiandrosterone Sulfate
Follicle Stimulating Hormone
Luteinizing Hormone
LDL Cholesterol
HDL Cholesterol
Androgens
Observational Studies
Testosterone
Estradiol
Body Mass Index

Keywords

  • Follistatin
  • HsCRP
  • Obesity
  • Oral contraceptives
  • Polycystic ovary syndrome

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynaecology

Cite this

Increased follistatin levels after oral contraceptive treatment in obese and non-obese women with polycystic ovary syndrome. / Chen, Mei Jou; Yang, Wei Shiung; Chen, Hsin Fu; Kuo, Jahn Jahn; Ho, Hong Nerng; Yang, Yu Shih; Chen, Shee Uan.

In: Human Reproduction, Vol. 25, No. 3, 01.01.2010, p. 779-785.

Research output: Contribution to journalArticle

Chen, Mei Jou ; Yang, Wei Shiung ; Chen, Hsin Fu ; Kuo, Jahn Jahn ; Ho, Hong Nerng ; Yang, Yu Shih ; Chen, Shee Uan. / Increased follistatin levels after oral contraceptive treatment in obese and non-obese women with polycystic ovary syndrome. In: Human Reproduction. 2010 ; Vol. 25, No. 3. pp. 779-785.
@article{0983a582b3ca45278f67420d12176e99,
title = "Increased follistatin levels after oral contraceptive treatment in obese and non-obese women with polycystic ovary syndrome",
abstract = "Background: Follistatin levels have recently been considered as a marker for inflammation. Our objective was to evaluate the level of circulating follistatin and high-sensitivity C-reactive protein (hsCRP) in women with polycystic ovary syndrome (PCOS) after oral contraceptive (OC) treatment. Methods: A total of 56 Taiwanese women with PCOS were enrolled in this prospective observational study in which they were treated for 3 months with OCs (ethinyl estradiol-cyproterone acetate). Blood samples were taken at baseline after treatment during the withdrawal bleed. Body mass index (BMI), lipid profiles, plasma follistatin, hsCRP, fasting glucose, insulin for the homeostasis model assessment of insulin resistance (HOMA-IR) and hormone profiles were measured and analyzed. Results: Total testosterone, free androgen index (FAI), dehydroepiandrosterone sulfate (DHEAS), follicle-stimulating hormone (FSH), luteinizing hormone (LH) and estradiol levels were significantly lower, but total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides, circulating follistatin and hsCRP were significantly higher than baseline in women with PCOS after treatment with OCs. An elevation of fasting insulin, HOMA-IR and hsCRP after OC treatment was more evident in non-obese than obese women, whereas the elevation of follistatin was significant in both obese and non-obese women. Follistatin and hsCRP levels all showed significant correlations with each other at baseline and after treatment. The differences in follistatin and hsCRP levels from baseline to after OC treatment were significantly associated with the difference in triglyceride levels. Conclusion: SBoth hsCRP and follistatin levels increase after OC treatment in women with PCOS. Follistatin seems more sensitive than hsCRP alone to represent the aggravated low-grade inflammatory status after OC treatment in obese and non-obese women with PCOS.",
keywords = "Follistatin, HsCRP, Obesity, Oral contraceptives, Polycystic ovary syndrome",
author = "Chen, {Mei Jou} and Yang, {Wei Shiung} and Chen, {Hsin Fu} and Kuo, {Jahn Jahn} and Ho, {Hong Nerng} and Yang, {Yu Shih} and Chen, {Shee Uan}",
year = "2010",
month = "1",
day = "1",
doi = "10.1093/humrep/dep459",
language = "English",
volume = "25",
pages = "779--785",
journal = "Human Reproduction",
issn = "0268-1161",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Increased follistatin levels after oral contraceptive treatment in obese and non-obese women with polycystic ovary syndrome

AU - Chen, Mei Jou

AU - Yang, Wei Shiung

AU - Chen, Hsin Fu

AU - Kuo, Jahn Jahn

AU - Ho, Hong Nerng

AU - Yang, Yu Shih

AU - Chen, Shee Uan

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Background: Follistatin levels have recently been considered as a marker for inflammation. Our objective was to evaluate the level of circulating follistatin and high-sensitivity C-reactive protein (hsCRP) in women with polycystic ovary syndrome (PCOS) after oral contraceptive (OC) treatment. Methods: A total of 56 Taiwanese women with PCOS were enrolled in this prospective observational study in which they were treated for 3 months with OCs (ethinyl estradiol-cyproterone acetate). Blood samples were taken at baseline after treatment during the withdrawal bleed. Body mass index (BMI), lipid profiles, plasma follistatin, hsCRP, fasting glucose, insulin for the homeostasis model assessment of insulin resistance (HOMA-IR) and hormone profiles were measured and analyzed. Results: Total testosterone, free androgen index (FAI), dehydroepiandrosterone sulfate (DHEAS), follicle-stimulating hormone (FSH), luteinizing hormone (LH) and estradiol levels were significantly lower, but total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides, circulating follistatin and hsCRP were significantly higher than baseline in women with PCOS after treatment with OCs. An elevation of fasting insulin, HOMA-IR and hsCRP after OC treatment was more evident in non-obese than obese women, whereas the elevation of follistatin was significant in both obese and non-obese women. Follistatin and hsCRP levels all showed significant correlations with each other at baseline and after treatment. The differences in follistatin and hsCRP levels from baseline to after OC treatment were significantly associated with the difference in triglyceride levels. Conclusion: SBoth hsCRP and follistatin levels increase after OC treatment in women with PCOS. Follistatin seems more sensitive than hsCRP alone to represent the aggravated low-grade inflammatory status after OC treatment in obese and non-obese women with PCOS.

AB - Background: Follistatin levels have recently been considered as a marker for inflammation. Our objective was to evaluate the level of circulating follistatin and high-sensitivity C-reactive protein (hsCRP) in women with polycystic ovary syndrome (PCOS) after oral contraceptive (OC) treatment. Methods: A total of 56 Taiwanese women with PCOS were enrolled in this prospective observational study in which they were treated for 3 months with OCs (ethinyl estradiol-cyproterone acetate). Blood samples were taken at baseline after treatment during the withdrawal bleed. Body mass index (BMI), lipid profiles, plasma follistatin, hsCRP, fasting glucose, insulin for the homeostasis model assessment of insulin resistance (HOMA-IR) and hormone profiles were measured and analyzed. Results: Total testosterone, free androgen index (FAI), dehydroepiandrosterone sulfate (DHEAS), follicle-stimulating hormone (FSH), luteinizing hormone (LH) and estradiol levels were significantly lower, but total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides, circulating follistatin and hsCRP were significantly higher than baseline in women with PCOS after treatment with OCs. An elevation of fasting insulin, HOMA-IR and hsCRP after OC treatment was more evident in non-obese than obese women, whereas the elevation of follistatin was significant in both obese and non-obese women. Follistatin and hsCRP levels all showed significant correlations with each other at baseline and after treatment. The differences in follistatin and hsCRP levels from baseline to after OC treatment were significantly associated with the difference in triglyceride levels. Conclusion: SBoth hsCRP and follistatin levels increase after OC treatment in women with PCOS. Follistatin seems more sensitive than hsCRP alone to represent the aggravated low-grade inflammatory status after OC treatment in obese and non-obese women with PCOS.

KW - Follistatin

KW - HsCRP

KW - Obesity

KW - Oral contraceptives

KW - Polycystic ovary syndrome

UR - http://www.scopus.com/inward/record.url?scp=76749131062&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76749131062&partnerID=8YFLogxK

U2 - 10.1093/humrep/dep459

DO - 10.1093/humrep/dep459

M3 - Article

AN - SCOPUS:76749131062

VL - 25

SP - 779

EP - 785

JO - Human Reproduction

JF - Human Reproduction

SN - 0268-1161

IS - 3

ER -